Cell and Molecular Physiology, Loyola University Chicago, Chicago, Illinois, United States of America.
Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom.
PLoS One. 2022 Mar 1;17(3):e0264430. doi: 10.1371/journal.pone.0264430. eCollection 2022.
Laminin N-terminus α31 (LaNt α31) is an alternative splice isoform derived from the laminin α3 gene. The LaNt α31 protein is enriched around the terminal duct lobular units in normal breast tissue. In the skin and cornea the protein influences epithelial cell migration and tissue remodelling. However, LaNt α31 has never been investigated in a tumour environment. Here we analysed LaNt α31 in invasive ductal carcinoma and determined its contribution to breast carcinoma invasion. LaNt α31 expression and distribution were analysed by immunohistochemistry in human breast tissue biopsy sections and tissue microarrays covering 232 breast cancer samples. This analysis revealed LaNt α31 to be upregulated in 56% of invasive ductal carcinoma specimens compared with matched normal tissue, and further increased in nodal metastasis compared with the tumour mass in 45% of samples. 65.8% of triple negative cases displayed medium to high LaNt α31 expression. To study LaNt α31 function, an adenoviral system was used to induce expression in MCF-7 and MDA-MB-231 cells. 2D cell migration and invasion into collagen hydrogels were not significantly different between LaNt α31 overexpressing cells and control treated cells. However, LaNt α31 overexpression reduced the proliferation rate of MCF-7 and MDA-MB-231 cells. Moreover, LaNt α31 overexpressing MDA-MB-231 cells displayed a striking change in their mode of invasion into laminin-containing Matrigel; changing from multicellular streaming to individual cellular-invasion. In agreement with these results, 66.7% of the tumours with the highest LaNt α31 expression were non-cohesive. Together these findings indicate that breast cancer-associated changes in LaNt α31 expression could contribute to the processes involved in tumour invasion and may represent a new therapeutic target.
层粘连蛋白 N 端 α31(LaNt α31)是从层粘连蛋白α3 基因衍生而来的一种替代剪接异构体。LaNt α31 蛋白在正常乳腺组织的终末导管小叶单位周围丰富。在皮肤和角膜中,该蛋白影响上皮细胞迁移和组织重塑。然而,LaNt α31 从未在肿瘤环境中进行过研究。在这里,我们分析了浸润性导管癌中的 LaNt α31,并确定了其对乳腺癌侵袭的贡献。通过免疫组织化学分析人乳腺组织活检切片和包含 232 个乳腺癌样本的组织微阵列,分析了 LaNt α31 的表达和分布。该分析显示,与匹配的正常组织相比,56%的浸润性导管癌标本中 LaNt α31 表达上调,与肿瘤组织相比,45%的淋巴结转移标本中 LaNt α31 进一步增加。65.8%的三阴性病例显示中至高 LaNt α31 表达。为了研究 LaNt α31 的功能,使用腺病毒系统在 MCF-7 和 MDA-MB-231 细胞中诱导表达。LaNt α31 过表达细胞与对照处理细胞之间,2D 细胞迁移和胶原凝胶侵袭无显著差异。然而,LaNt α31 过表达降低了 MCF-7 和 MDA-MB-231 细胞的增殖率。此外,LaNt α31 过表达的 MDA-MB-231 细胞在其侵入含有层粘连蛋白的 Matrigel 的模式上发生了明显变化;从多细胞流变成了单个细胞侵袭。与这些结果一致,66.7%表达最高 LaNt α31 的肿瘤是非凝聚性的。这些发现表明,乳腺癌相关的 LaNt α31 表达变化可能有助于肿瘤侵袭涉及的过程,并可能代表新的治疗靶点。